5302392025-04-012025-06-305302392025-04-012025-06-30in-capmkt:OtherExpenses1Member5302392025-04-012025-06-30in-capmkt:OtherExpenses2Memberiso4217:INRiso4217:INRxbrli:shares530239SUVENNOTLISTEDINE495B01038SUVEN LIFE SCIENCES LIMITEDMain BoardEquity2025-04-012026-03-312025-08-132025-08-05INRLakhsQuarterlyFirst quarterSingle segmentThe Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented2025-08-1311:30:002025-08-1312:30:00Not applicablefalsefalseNil2025-04-012025-06-30UnauditedStandalone186670005890000245570000005975600001368400098904000172344000-1477870000-1477870000000-1477870000000-147787000-150000-1479370002180740001-0.68-0.6800-0.68-0.68 <BR> <BR> 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 13, 2025. The results for the quarter ended June 30, 2025 has been reviewed by our statutory auditors. <BR> 2) 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. <BR> 3) 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc. <BR> 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. <BR> 5) ESOP: For the quarter ended June 2025, the Company recognized an employee benefit expense (EBP) of Rs. 27.38 lakhs in accordance with Ind AS 102 – Share-based Payment. The cumulative EBP recognized as of June 2025 amounts to Rs.154.83 lakhs. During the quarter, out of 2,21,800 options under the 1st tranche, 1,93,500 options were exercised and the Company received Rs. 106.43 lakhs pursuant to the exercise of employee stock options under its SLSL ESOP 2020 scheme. As of the reporting date, the equity shares corresponding to these exercised options had not yet been allotted. The remaining unexercised options under the 1st tranche continue to be available for exercise by eligible employees until 06-May-2027. <BR> 6) Preferential Issue: The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025. <BR> Each warrant is convertible into one equity share of face value Rs.1 at an exercise price of Rs.134 per share, within a period of 18 months from the date of allotment. <BR> As per the terms of issue: <BR> 1. 25% of the warrant price is payable at the time of allotment. <BR> 2. The balance 75% is payable upon exercise of the warrant, prior to allotment of equity shares. <BR> Particulars Amount in Lakhs <BR> 25% upfront received from 23 allottees 21,441.00 <BR> Balance 75% received from 2 allottees 7,724.93 <BR> Total money received as on 30th June 2025 29,165.93 <BR> 7) The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year. <BR> R & D Expenses51877000Other Expenses470270001500000-150000